Approval of Biogen's high-dose Spinraza strengthens the company’s lifecycle strategy in SMA, enhancing durability while reinforcing competitive positioning in a rapidly evolving neurology market.
Feliza Mirasol
Advertisement
Feliza Mirasol is the science editor for BioPharm International.
Articles by Feliza Mirasol
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Insilico Enter $2.75 Billion Research and Licensing Agreement to Advance AI Drug Discovery
2
Eli Lilly Seeks Agreement with U.K. Government to Raise Prices for Medicines: Report
3
How Does MFN Pricing Work Within TrumpRx?
4
Pharma M&A Roundup: Novartis to Acquire Excellrgy Inc., Otsuka Pharmaceutical to Acquire Transcend Therapeutics
5